Known targets — ChEMBL curated mechanism
CHRM1DRD2DRD3DRD4HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR2APDE3ASIGMAR1
The experimentally established mechanism targets of Lactic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.69 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.38 |
| ▸ | TET2 | Q6N021 | 3/20 | 0.38 |
| ▸ | KDM4A | O75164 | 2/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.38 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.38 |
| ▸ | TET3 | O43151 | 1/20 | 0.38 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lactic Acid SCHEMBL13505613 | 1.00 | TP53 (0.69) | TP53OR51E2CYP1A2SMN1; SMN2CYP2C9 | |
| Lactic Acid SCHEMBL7026852 | 1.00 | TP53 (0.69) | TP53OR51E2CYP1A2SMN1; SMN2CYP2C9 | |
| Lactic Acid SCHEMBL4263083 | 1.00 | TP53 (0.69) | TP53OR51E2CYP1A2SMN1; SMN2CYP2C9 | |
| Lactic Acid SCHEMBL41708 | 1.00 | TP53 (0.69) | TP53OR51E2CYP1A2SMN1; SMN2CYP2C9 | |
| Lactic Acid SCHEMBL424598 | 1.00 | TP53 (0.69) | TP53OR51E2CYP1A2SMN1; SMN2CYP2C9 | |
| Lactic Acid SCHEMBL4261279 | 1.00 | TP53 (0.69) | TP53OR51E2CYP1A2SMN1; SMN2CYP2C9 | |
| Lactic Acid SCHEMBL3845012 | 1.00 | TP53 (0.69) | TP53OR51E2CYP1A2SMN1; SMN2CYP2C9 | |
| Lactic Acid SCHEMBL5269783 | 1.00 | TP53 (0.69) | TP53OR51E2CYP1A2SMN1; SMN2CYP2C9 | |
| Lactic Acid SCHEMBL2286708 | 1.00 | TP53 (0.69) | TP53OR51E2CYP1A2SMN1; SMN2CYP2C9 | |
| Lactic Acid SCHEMBL15008846 | 0.97 | TP53 (0.65) | TP53OR51E2CYP1A2SMN1; SMN2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118217226-A | Photo-thermal composite hydrogel with adjustable slow release performance and preparation method thereof | 西北有色金属研究院 | 2024-06-21 | — | — | CN | claimed |
| CN-118217226-A | Photo-thermal composite hydrogel with adjustable slow release performance and preparation method thereof | 西北有色金属研究院 | 2024-06-21 | — | — | CN | disclosed |
| US-20200360391-A1 | Medicinal Composition for Treating Intractable Heart Disease | OSAKA UNIVERSITY (JP) | 2020-11-19 | — | — | US | disclosed |
| US-10632079-B2 | Microspheres having core/shell structure | OTSUKA PHARMACEUTICALS CO., LTD. (JP) | 2020-04-28 | — | — | US | disclosed |
| EP-3569249-A1 | MEDICINAL COMPOSITION FOR TREATING INTRACTABLE HEART DISEASE | Osaka University (JP) | 2019-11-20 | — | — | EP | disclosed |
| US-20190343841-A1 | Medicinal Composition for Treating Intractable Heart Disease | OSAKA UNIVERSITY (JP) | 2019-11-14 | — | — | US | disclosed |
| EP-2351574-B1 | PROMOTER FOR REGENERATION OF TENDON-BONE JUNCTION TISSUE OR LIGAMENT-BONE JUNCTION TISSUE | KRINGLE PHARMA INC (JP) | 2016-08-24 | — | — | EP | disclosed |
| US-8927493-B2 | Promoter for regeneration of tendon-bone junction tissue or ligament-bone junction tissue | KRINGLE PHARMA, INC. (JP) | 2015-01-06 | — | — | US | disclosed |
| EP-2170300-B1 | MICROSPHERES HAVING CORE/SHELL STRUCTURE | OTSUKA PHARMA CO LTD (JP) | 2014-12-31 | — | — | EP | disclosed |
| EP-2515878-B1 | SUSTAINED-RELEASE FORMULATION | TAKEDA PHARMACEUTICAL (JP) | 2013-10-30 | — | — | EP | disclosed |
| EP-0765660-A2 | Microcapsules comprising 2-piperazinone-1-acetic acid compounds | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-04-02 | — | — | EP | disclosed |
| WO-1997001331-A2 | METHOD OF PRODUCING SUSTAINED-RELEASE PREPARATION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-01-16 | — | — | WO | disclosed |
| US-5594091-A | POLYLACTONES FOR MICROCAPSULES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-01-14 | — | — | US | disclosed |
| US-5534269-A | Method of producing sustained-release preparation | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-07-09 | — | — | US | disclosed |
| EP-0709085-A1 | Sustained-release preparation | Takeda Chemical Industries, Ltd. (JP) | 1996-05-01 | — | — | EP | disclosed |
| WO-1996007399-A1 | SUSTAINED RELEASE PREPARATION CONTAINING METAL SALT OF A PEPTIDE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-03-14 | — | — | WO | disclosed |
| US-5480868-A | Sustained-release preparation | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-01-02 | — | — | US | disclosed |
| EP-0647449-A1 | Sustained-release preparation of anti-endothelin substance | Takeda Chemical Industries, Ltd. (JP) | 1995-04-12 | — | — | EP | disclosed |
| EP-0633020-A1 | Method of producing sustained-release preparation | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-01-11 | — | — | EP | disclosed |
| EP-0601799-A1 | Sustained-release preparation | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-06-15 | — | — | EP | disclosed |